Study of PD-L1 antibody plus chemo before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding a PD-L1 antibody (Adabelimab) to standard chemotherapy before surgery can help treat advanced head and neck squamous cell carcinoma. It is for people who have not had treatment for this cancer before and are well enough to undergo the therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have head and neck squamous cell carcinoma confirmed by biopsy.
- You cannot have had any prior treatment for this cancer.
- Your cancer must be stage III to IVB (advanced but not spread far).
- You must be in fairly good health (ECOG score 0 or 1).
- Your blood counts and liver/kidney function must be within certain limits.
- You must agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Pabliximab given before surgery for head and neck cancer. It aims to see if it can help shrink tumors and improve outcomes for people with a specific type of cancer that can be removed surgically.
This trial tests a combination of penpulimab (an immunotherapy drug) and chemotherapy before and after surgery for head and neck cancer. The goal is to see if this approach can improve treatment outcomes for people with resectable (removable by surgery) cancers.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests a combination of two drugs (Adebrelimab, an immunotherapy that helps your immune system attack cancer cells, and Dalpiciclib, a targeted therapy that stops cancer cells from dividing) given before surgery for a type of head and neck cancer. It is looking at whether this treatment can improve outcomes for people with HPV-negative, locally advanced head and neck squamous cell carcinoma that can be surgically removed.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This trial tests an immunotherapy drug (anti-PD-1) given before surgery for head and neck cancer that has come back or spread. The goal is to see if it helps shrink the tumor and improve outcomes.
Hear when a new Squamous Cell Carcinoma of Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.